.Nature Medication, Published online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- drug conjugate (ADC) tisotumab vedotin led to improved progression-free and general survival, bring about FDA approval and a new therapy possibility for patients.